Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1937

Sort by

Sort Order Select

Journal Articles

Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia

Jenny Klintman, Niamh Appleby, Basile Stamatopoulos, Katie Ridout, Toby A. Eyre, Pauline Robbe, Laura Lopez Pascua, Samantha J. L. Knight, Helene Dreau, Maite Cabes, Niko Popitsch, Mats Ehinger, Jose I. Martín-Subero, Elías Campo, Robert Månsson, Davide Rossi, Jenny C. Taylor, Dimitrios V. Vavoulis, Anna Schuh

Blood (2021) 137 (20): 2800–2816.

https://doi.org/10.1182/blood.2020005650

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Blood (2021) 137 (17): 2307–2320.

https://doi.org/10.1182/blood.2020008750

Published: 2021

Includes: Supplemental data

Journal Articles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic, PhD, Verena Passerini, PhD, Mikkel Z Oestergaard, PhD, Andrea Knapp, PhD, Kirsten Mundt, PhD, Shamzah Araf, MRCP, MBBS, PhD, Julia Richter, PhD, Jude Fitzgibbon, PhD, Wolfram Klapper, Robert E. Marcus, FRCP, Andrew Davies, MD PhD, Michael Herold, MD, Wolfgang Hiddemann, PhD, Michael Unterhalt, PhD, Eva Hoster, PhD, Oliver Weigert, MD

Blood (2019) 134 (Supplement_1): 122.

https://doi.org/10.1182/blood-2019-130208

Published: 2019

Journal Articles

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Blood (2019) 134 (Supplement_1): 463.

https://doi.org/10.1182/blood-2019-127811

Published: 2019

Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 464.

https://doi.org/10.1182/blood-2019-122781

Published: 2019

Journal Articles

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

Juan J. Gu, MD PhD, Yizhen Liu, MD PhD, Jia Jin, Ling Yang, Zuguang Xia, Xiaojian Liu, Fangfang Lv, MD, Francisco J. Hernandez-Ilizaliturri, MD, Xiaonan Hong, Junning Cao, MD, Qunling Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 5233.

https://doi.org/10.1182/blood-2019-128878

Published: 2019

Journal Articles

HIF-1a Regulating the Chemoresistance By Upregulating the Expression of xCT and GCLM in the Diffuse Large B Cell Lymphoma

Yongqiang Wei, PhD, Hong Zeng, Xiaolei Wei, PhD, Weimin Huang, PhD, Jialin Song, Jingxia Zheng, Ru Feng, MD

Blood (2019) 134 (Supplement_1): 5236.

https://doi.org/10.1182/blood-2019-127612

Published: 2019

Journal Articles

Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients

Anna Vanazzi, MD, Fedro Peccatori, MD, Barbara Buonomo, MD, Di Loreto Eugenia, MD, Giovanna Scarfone, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5289.

https://doi.org/10.1182/blood-2019-127391

Published: 2019

Journal Articles

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

Shonali Midha, MD, Julio C. Chavez, MD, Hayder Saeed, MD, Celeste Bello, MD, Farhad Khimani, MD, Silvia Tse Bunting, MD MSc, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 5347.

https://doi.org/10.1182/blood-2019-130721

Published: 2019

Journal Articles

Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence

Blood (2019) 134 (Supplement_1): 5288.

https://doi.org/10.1182/blood-2019-126434

Published: 2019

Journal Articles

The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States: A Comprehensive Literature Review

Crystal Watson, MS, Arie Barlev, PharmD, Jodie Worrall, Steve Duff, MS, Rachel Beckerman, PhD

Blood (2019) 134 (Supplement_1): 5826.

https://doi.org/10.1182/blood-2019-122611

Published: 2019

Journal Articles

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Keri Keri Yang, Beth Lesher, PharmD, Eleanor Lucas, BA, Tony Caver, PhD, Boxiong Tang, MD PhD

Blood (2019) 134 (Supplement_1): 5881.

https://doi.org/10.1182/blood-2019-130896

Published: 2019

Journal Articles

Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity

Faouzi Djebbari, Furqaan Kaji, Louise Stanton, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Toby A. Eyre

Blood (2019) 134 (Supplement_1): 5884.

https://doi.org/10.1182/blood-2019-122213

Published: 2019

Journal Articles

Prophylactic Use of Filgrastim on Days 7, 11 and 14 in Patients Receiving R-CHOP for Non-Hodgkin's Lymphoma

Sherief El- Shakankery, MPharm, Sumantha Gabriel, BPharm, Emma Groves, M Pharm

Blood (2019) 134 (Supplement_1): 5887.

https://doi.org/10.1182/blood-2019-124329

Published: 2019

Journal Articles

Chemotherapy Effect on Fertility in Male Patients with Hodgkin and Non-Hodgkin Lymphoma

Ahmed Alaskar, Naila Shaheen, Saba Alsuhaymi, Nouf Alqahtani, Nouf Bin Muammar, Zaha Jamaan, Noura Alhmanai, Mohsen Alhazmi, Shatry Hind, May Anne Mendoza, Ayman Alhejazi, MD, Khadega Abuelgasim, Giamal Gmati, Moussab Damlaj, Hind Salama, Mohsen Alzahrani, Bader Alahmari, Mahmoud Salam, Abin Thomas

Blood (2019) 134 (Supplement_1): 5865.

https://doi.org/10.1182/blood-2019-126447

Published: 2019

Journal Articles

Alterations in Secretome and Transcriptome of Bone Marrow Derived MSCs in Patients with Diffuse Large B-Cell Lymphoma without Bone Marrow Involvement

Nataliya A. Petinati, MD PhD, Natalia Sats, PhD, Nina J. Drize, PhD, Irina Malyants, Victoria Shender, PhD, Ksenia Anufrieva, PhD, Polina Shneider, Tatiana Grigorieva, PhD, Georgiy Arapidi, PhD, Maria Lagarkova, PhD, Ekaterina A. Fastova, MD, Aminat A. Magomedova, MD PhD, Sergey K. Kravchenko, MD PhD, Valeriy G. Savchenko, MD PhD

Blood (2019) 134 (Supplement_1): 1514.

https://doi.org/10.1182/blood-2019-122431

Published: 2019

Journal Articles

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Kathrine T. Isaksen, MD, Klaus Beiske, MD PhD, Erlend B. Smeland, MD PhD, Judit Jørgensen, MD PhD, Marianne Brodtkorb, MD PhD, June Helen Myklebust, PhD, Mats Jerkeman, MD Professor, Leo Meriranta, MD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sirpa Leppa, MD PhD, David W. Scott, MBChB, PhD, Harald Holte, MD PhD, Yngvild Nuvin Blaker, MD PhD

Blood (2019) 134 (Supplement_1): 1485.

https://doi.org/10.1182/blood-2019-121467

Published: 2019

Journal Articles

Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways

Blood (2019) 134 (Supplement_1): 1480.

https://doi.org/10.1182/blood-2019-126860

Published: 2019

Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3983.

https://doi.org/10.1182/blood-2019-129756

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

HIF-1a Regulating the Chemoresistance By Upregulating the Expression of xCT and GCLM in the Diffuse Large B Cell Lymphoma

Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence

The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States: A Comprehensive Literature Review

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity

Prophylactic Use of Filgrastim on Days 7, 11 and 14 in Patients Receiving R-CHOP for Non-Hodgkin's Lymphoma

Chemotherapy Effect on Fertility in Male Patients with Hodgkin and Non-Hodgkin Lymphoma

Alterations in Secretome and Transcriptome of Bone Marrow Derived MSCs in Patients with Diffuse Large B-Cell Lymphoma without Bone Marrow Involvement

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only